GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Enterprise Value

Sinopharm Group Co (Sinopharm Group Co) Enterprise Value : $10,044 Mil (As of Apr. 27, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sinopharm Group Co's Enterprise Value is $10,044 Mil. Sinopharm Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $1,659 Mil. Therefore, Sinopharm Group Co's EV-to-EBIT ratio for today is 6.05.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Sinopharm Group Co's Enterprise Value is $10,044 Mil. Sinopharm Group Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $1,659 Mil. Therefore, Sinopharm Group Co's EV-to-EBITDA ratio for today is 6.05.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Sinopharm Group Co's Enterprise Value is $10,044 Mil. Sinopharm Group Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $40,773 Mil. Therefore, Sinopharm Group Co's EV-to-Revenue ratio for today is 0.25.


Sinopharm Group Co Enterprise Value Historical Data

The historical data trend for Sinopharm Group Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Enterprise Value Chart

Sinopharm Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16,912.75 15,644.34 16,880.30 15,980.63 15,572.64

Sinopharm Group Co Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,022.87 15,980.63 23,754.28 9,120.13 15,572.64

Competitive Comparison of Sinopharm Group Co's Enterprise Value

For the Medical Distribution subindustry, Sinopharm Group Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's Enterprise Value Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Enterprise Value falls into.



Sinopharm Group Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Sinopharm Group Co's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

Sinopharm Group Co's Enterprise Value for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDF) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Sinopharm Group Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10043.879/1658.99
=6.05

Sinopharm Group Co's current Enterprise Value is $10,044 Mil.
Sinopharm Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,659 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Sinopharm Group Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=10043.879/1658.99
=6.05

Sinopharm Group Co's current Enterprise Value is $10,044 Mil.
Sinopharm Group Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,659 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Sinopharm Group Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10043.879/40772.779
=0.25

Sinopharm Group Co's current Enterprise Value is $10,044 Mil.
Sinopharm Group Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $40,773 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co (Sinopharm Group Co) Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (Sinopharm Group Co) Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016